Statistiche di base
| LEI | 549300LQXD6M2MIQFN24 |
| CIK | 1855644 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to JATT Acquisition Corp - Class A
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| September 4, 2025 |
Exhibit 99.1 Advancing Dual - Pathway Biologic Candidates in Autoimmune and Inflammatory Diseases September 2025 Nasdaq Ticker: ZURA ©2025 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 . Words such as “expect,” “estimate,” “pr |
|
| September 4, 2025 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 4, 2025 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorpor |
|
| August 20, 2025 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 20, 2025 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporat |
|
| August 20, 2025 |
Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference Exhibit 99.1 Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference HENDERSON, Nev. – (BUSINESS WIRE) – August 20, 2025 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today announced that its senior leadership |
|
| August 14, 2025 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 14, 2025 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporat |
|
| August 14, 2025 |
Non-Employee Director Compensation Policy. Exhibit 10.1 Zura Bio Limited Non-Employee Director Compensation Policy Adopted: April 22, 2025 Each member of the Board of Directors (the “Board”) of Zura Bio Limited, a Cayman Islands exempted company (the “Company”), who is not also serving as an employee of or consultant to the Company or any of its subsidiaries (each such member, an “Eligible Director”), will receive the compensation describe |
|
| August 14, 2025 |
Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates Exhibit 99.1 Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates · Initiated TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe hidradenitis suppurativa (HS) in Q2 2025 · Continued progress in the Phase 2 TibuSURE clinical study evaluating tibulizumab in adults with systemic sclerosis (SSc) · Appointed new executive |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001 |
|
| July 1, 2025 |
Exhibit 10.1 June 27, 2025 Via E-Mail Eric Hyllengren [email protected] Dear Eric, Congratulations! I am delighted to make you an offer for the full-time position of Chief Financial Officer (“CFO”) for the Zura Bio Group (including Zura Bio Inc., a subsidiary of Zura Bio Limited, together with its affiliated companies (the “Company”)) reporting to the Chief Executive Officer. Your anticipate |
|
| July 1, 2025 |
Zura Bio Announces Chief Financial Officer Transition Exhibit 99.1 Zura Bio Announces Chief Financial Officer Transition HENDERSON, NV - (BUSINESS WIRE) – July 1, 2025 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7 |
|
| July 1, 2025 |
Settlement Agreement, by and between the Company and Verender Badial, dated as of June 27, 2025. Exhibit 10.2 WITHOUT PREJUDICE AND SUBJECT TO CONTRACT SETTLEMENT AGREEMENT THIS AGREEMENT is made on 27 June 2025 BETWEEN: (1) Zura Bio Limited incorporated and registered in England and Wales with company number 13856620 whose registered office is at 3rd Floor 1 Ashley Road, Altrincham, Cheshire, United Kingdom, WA14 2DT (the "Company"); (2) Verender Badial of Dalriada House, Cryfield Grange Roa |
|
| July 1, 2025 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 25, 2025 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporatio |
|
| June 4, 2025 |
Exhibit 99.1 Advancing Dual-Pathway Biologic Candidates Addressing Unmet Needs in Autoimmune and Inflammatory Diseases Jefferies Global Healthcare Conference 2025 Wednesday, June 4, 2025 New York City #JefferiesHealthcare Nasdaq Ticker: ZURA ©2025 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes “forward-looking statements” within the meaning of the “safe harbor” p |
|
| June 4, 2025 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 4, 2025 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation |
|
| May 27, 2025 |
Zura Bio to Present at the Jefferies Global Healthcare Conference Exhibit 99.1 Zura Bio to Present at the Jefferies Global Healthcare Conference HENDERSON, Nev. – (BUSINESS WIRE) – May 27, 2025 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced that members of its senior leadership team will |
|
| May 27, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 27, 2025 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation |
|
| May 23, 2025 |
Submission of Matters to a Vote of Security Holders Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporatio |
|
| May 22, 2025 |
May 22, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Jenn Do Kevin Vaughn Re: Zura Bio Limited Form 10-K for Fiscal Year Ended December 31, 2024 File No. 001-40598 Dear Jenn Do and Kevin Vaughn: We are writing in response to the comments received from the staff (the “Staff”) of the Sec |
|
| May 20, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 20, 2025 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation |
|
| May 20, 2025 |
Exhibit 99.1 Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa · TibuSHIELD has launched with the activation of its first clinical site · This study is the first to evaluate dual inhibition of B-cell activating factor (BAFF) and interleukin-17A (IL-17A) pathways in adults with moderate to severe hidradenitis suppurativa (HS) · TibuSHI |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 00 |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 8, 2025 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) |
|
| May 8, 2025 |
Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates Exhibit 99.1 Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates · Advanced the Phase 2 TibuSURE clinical trial evaluating tibulizumab in adults with systemic sclerosis (SSc) · Continued preparations for the planned Phase 2 trial evaluating tibulizumab in adults with hidradenitis suppurativa (HS), expected to initiate in Q2 2025 · Strengthened the team with a strateg |
|
| April 23, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 17, 2025 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 16, 2025 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporati |
|
| April 17, 2025 |
Exhibit 4.1 Form of Warrant THE OFFER AND SALE OF THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, |
|
| April 17, 2025 |
Exhibit 10.1 SHARE SURRENDER AND WARRANT AGREEMENT April 16, 2025 Zura Bio Limited c/o Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands Re: Share Surrender and Warrant Agreement Ladies and Gentlemen: This letter agreement (the “Agreement”) confirms the agreement of Zura Bio Limited, an exempted company incorporated under the laws of the Cayman Isla |
|
| April 17, 2025 |
Exhibit 10.2 SHARE SURRENDER AND WARRANT AGREEMENT April 17, 2025 Zura Bio Limited c/o Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands Re: Share Surrender and Warrant Agreement Ladies and Gentlemen: This letter agreement (the “Agreement”) confirms the agreement of Zura Bio Limited, an exempted company incorporated under the laws of the Cayman Isla |
|
| March 25, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 25, 2025 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporati |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-405 |
|
| March 25, 2025 |
Exhibit 19.1 ZURA BIO LIMITED INSIDER TRADING POLICY I.Purpose This Insider Trading Policy (this “Policy”) states the policy with respect to transactions in the securities of Zura Bio Limited (the “Company”), and the handling of confidential information about the Company and other companies with which the Company does business. The Company’s Board of Directors has adopted this Policy to promote co |
|
| March 25, 2025 |
Description of Registrant’s securities. Exhibit 4.6 DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED General We are a company incorporated in the Cayman Islands as an exempted company and our affairs are governed by our Second Amended and Restated Memorandum and Articles of Association (the “MAA”), the Cayman Islands Companies Act and the common law of the Cayma |
|
| March 25, 2025 |
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates Exhibit 99.1 Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates · Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline · Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc) · Completed a $112.5 million private placement financing in April 2024, contributing t |
|
| March 25, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 25, 2025 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporati |
|
| March 25, 2025 |
Exhibit 99.1 ©2025 Zura Bio Ltd. Nasdaq Ticker: ZURA Advancing Dual - Pathway Biologic Candidates: Addressing Unmet Needs in Autoimmune and Inflammatory Diseases March 2025 ©2025 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 . |
|
| February 24, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 24, 2025 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorpor |
|
| February 24, 2025 |
Zura Bio to Present at the Leerink Partners Global Healthcare Conference EX-99.1 2 tm257217d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Zura Bio to Present at the Leerink Partners Global Healthcare Conference HENDERSON, Nev. – (BUSINESS WIRE) – February 24, 2025 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its |
|
| February 14, 2025 |
EX-99.1 2 ex-99-02142025110242.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United State |
|
| January 13, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 13, 2025 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorpora |
|
| January 13, 2025 |
Exhibit 99.1 ©2025 Zura Bio Ltd. Nasdaq Ticker: ZURA Advancing Dual - Pathway Biologic Candidates: Addressing Unmet Needs in Autoimmune and Inflammatory Diseases January 2025 ©2024 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 |
|
| December 23, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 23, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorpor |
|
| December 23, 2024 |
Exhibit 99.1 Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults with Systemic Sclerosis · TibuSURE is the first clinical trial designed to investigate anti-BAFF and IL-17 pathways in systemic sclerosis. · TibuSURE launches with the initiation of its first clinical site. HENDERSON, Nev. – (BUSINESS WIRE) – December 23, 2024 – Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio |
|
| November 25, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 25, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorpor |
|
| November 25, 2024 |
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference Exhibit 99.1 Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference HENDERSON, Nev. – (BUSINESS WIRE) – November 25, 2024 – Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in |
|
| November 14, 2024 |
ZURA / Zura Bio Limited / GREAT POINT PARTNERS LLC Passive Investment SC 13G/A 1 greatpoint-zura093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ZURA BIO LIMITED (Name of Issuer) Class A Ordinary Shares, $0.0001 par value (Title of Class of Securities) G9TY5A101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check t |
|
| November 14, 2024 |
ZURA / Zura Bio Limited / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d1152794313g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Zura Bio Limited (Name of Issuer) Class A Ordinary Shares, $0.0001 par value (Title of Class of Securities) G9TY5A101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| November 14, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 14, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorpor |
|
| November 14, 2024 |
Exhibit 99.1 Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis HENDERSON, Nev. – (BUSINESS WIRE) – November 14, 2024 – Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, tod |
|
| November 14, 2024 |
SC 13G/A 1 tm2428137d20sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Zura Bio Limited (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G9TY5A101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this St |
|
| November 14, 2024 |
ZURA / Zura Bio Limited / ADAR1 Capital Management, LLC - SC 13G Passive Investment SC 13G 1 tm2428381d4sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* ZURA BIO LIMITED (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G9TY5A101 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) C |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40598 ZURA B |
|
| November 7, 2024 |
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates Exhibit 99.1 Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates · Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 · Cash, cash equivalents and investments totaling $188.2 million as of September 30, 2024, are anticipated to support operations, as currently |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorpora |
|
| October 30, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 30, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorpora |
|
| October 30, 2024 |
Zura Bio to Participate in Two Upcoming Investor Conferences in November Exhibit 99.1 Zura Bio to Participate in Two Upcoming Investor Conferences in November HENDERSON, Nev. – (BUSINESS WIRE) – October 30, 2024 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in tw |
|
| October 29, 2024 |
Submission of Matters to a Vote of Security Holders Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorpor |
|
| October 18, 2024 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorpor |
|
| September 23, 2024 |
ZURA / Zura Bio Limited / Athanor Capital, Lp Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.1)* Zura Bio Ltd (Name of Issuer) Class A Ordinary Shares (Title of Class of Securities) G9TY5A101 (CUSIP Number) September 11, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| September 16, 2024 | ||
| September 16, 2024 |
Zura Bio Limited 1489 W. Warm Springs Rd. #110 Henderson, NV 89014 Zura Bio Limited 1489 W. Warm Springs Rd. #110 Henderson, NV 89014 September 16, 2024 VIA EDGAR Division of Corporation Finance Office of Technology United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: Zura Bio Limited Registration Statement on Form S-3 File No. 333-281905 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Exchange Act of 1933 |
|
| September 13, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| September 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ De |
|
| September 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Class A Ordinary Shares, par value $0. |
|
| September 11, 2024 |
As filed with the Securities and Exchange Commission on September 11, 2024 As filed with the Securities and Exchange Commission on September 11, 2024 Registration No. |
|
| September 9, 2024 |
Exhibit 99.1 ©2024 Zura Bio Ltd. Nasdaq Ticker: ZURA Three Unique Dual-Pathway Biologics, Clinically Validated for Therapeutic Areas with Unmet Needs September 2024 ©2024 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such |
|
| September 9, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 9, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorpor |
|
| September 5, 2024 |
As filed with the Securities and Exchange Commission on September 5, 2024. As filed with the Securities and Exchange Commission on September 5, 2024. Registration No. 333-272628 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZURA BIO LIMITED (Exact name of Registrant as specified in its charter) Cayman Islands 6770 98-172573 (State or ot |
|
| September 5, 2024 |
As filed with the Securities and Exchange Commission on September 5, 2024. As filed with the Securities and Exchange Commission on September 5, 2024. Registration No. 333-279719 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZURA BIO LIMITED (Exact name of Registrant as specified in its charter) Cayman Islands 6770 98-172573 (State or ot |
|
| September 3, 2024 |
Exhibit 4.3 Zura Bio Limited, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section 2. |
|
| September 3, 2024 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 3, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorpor |
|
| September 3, 2024 |
Zura Bio to Present at Three Upcoming Investor Conferences in September Exhibit 99.1 Zura Bio to Present at Three Upcoming Investor Conferences in September Henderson, Nev. – September 3, 2024 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will present at three upcoming investor |
|
| September 3, 2024 |
Sales Agreement, by and between Zura Bio Limited and Leerink Partners LLC, dated September 3, 2024. Exhibit 1.2 ZURA BIO LIMITED US$125,000,000 CLASS A ORDINARY SHARES SALES AGREEMENT September 3, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Zura Bio Limited, a Cayman Islands exempted company (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1. Issuance and |
|
| September 3, 2024 |
As filed with the Securities and Exchange Commission on September 3, 2024 As filed with the Securities and Exchange Commission on September 3, 2024 Registration No. |
|
| September 3, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Debt Debt Securities Rule 457(o) (1) (2) (2) Equity Class A Ordinary Shares, par value $0. |
|
| August 21, 2024 |
Exhibit 10.1 SHARE SURRENDER AND WARRANT AGREEMENT August 15, 2024 Zura Bio Limited c/o Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands Re: Share Surrender and Warrant Agreement Ladies and Gentlemen: This letter agreement (the “Agreement”) confirms the agreement of Zura Bio Limited, an exempted company incorporated under the laws of the |
|
| August 21, 2024 |
Exhibit 4.1 THE OFFER AND SALE OF THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATIO |
|
| August 21, 2024 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 15, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporat |
|
| August 14, 2024 |
Exhibit 99.1 ©2024 Zura Bio Ltd. Nasdaq Ticker: ZURA Three unique dual - pathway biologics, clinically validated for therapeutic areas with unmet needs August 2024 ©2024 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 . Words su |
|
| August 14, 2024 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 14, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporat |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001 |
|
| August 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 13, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporat |
|
| August 13, 2024 |
Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights Exhibit 99.1 Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and inflammatory diseases - Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in 4Q 2024 and hidradenitis |
|
| August 13, 2024 |
ZURA BIO LIMITED Resale of Up To 41,596,750 Class A Ordinary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-279719 PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus dated June 4, 2024) ZURA BIO LIMITED Resale of Up To 41,596,750 Class A Ordinary Shares This prospectus supplement updates and supplements the prospectus, dated June 4, 2024 (as supplemented to date, the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-279719) |
|
| August 12, 2024 |
Exhibit 99.1 Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants Henderson, NV, August 12, 2024 – Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has completed its |
|
| August 12, 2024 |
Exhibit 10.1 AMENDMENT NO. 1 TO WARRANT AGREEMENT This amendment (this “Amendment”) is made as of August 12, 2024, by and between Zura Bio Limited, a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”), and constitutes an amendment to that certain Warrant Agreement, dated as of July 16, 2021 |
|
| August 12, 2024 |
Amendment to Warrant Agreement, dated August 12, 2024 Exhibit 10.1 AMENDMENT NO. 1 TO WARRANT AGREEMENT This amendment (this “Amendment”) is made as of August 12, 2024, by and between Zura Bio Limited, a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”), and constitutes an amendment to that certain Warrant Agreement, dated as of July 16, 2021 |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 ZURA BIO LIMITED (Exact name of Registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 ZURA BIO LIMITED (Exact name of Registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2024 |
Exhibit 99.1 Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants Henderson, NV, August 12, 2024 – Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has completed its |
|
| August 9, 2024 |
EX-99.1 2 tm2421034d2ex99-1.htm EXHIBIT 99-1 Exhibit 99.1 Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants Henderson, NV, August 9, 2024 – Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced th |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 ZURA BIO LIMITED (Exact name of Registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission F |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 ZURA BIO LIMITED (Exact name of Registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission F |
|
| August 9, 2024 |
Exhibit 99.1 Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants Henderson, NV, August 9, 2024 – Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the expiration and results of its previously an |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) ZURA BIO LIMITED (Name of Subject Company and Filing Person (Issuer)) Warrants to Acquire Class A Ordinary Shares G9TY5A119 (Title of Class of Securities) (CUSIP Number of Class of Securities) Robert L |
|
| August 8, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-280763 PROSPECTUS/OFFER TO EXCHANGE ZURA BIO LIMITED Offer to Exchange Warrants to Acquire Class A Ordinary Shares of ZURA BIO LIMITED for Class A Ordinary Shares of ZURA BIO LIMITED and Consent Solicitation THE OFFER PERIOD (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M., EASTERN TIME, ON AUGUST 8, 2024, |
|
| August 6, 2024 |
Zura Bio Limited 1489 W. Warm Springs Rd. #110 Henderson, NV 89014 Zura Bio Limited 1489 W. Warm Springs Rd. #110 Henderson, NV 89014 August 6, 2024 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Zura Bio Limited Registration Statement on Form S-4 File No. 333-280763 Ladies and Gentlemen: Zura Bio Limited hereby requests that the effective date and time of the above referenced Registration Statement |
|
| July 25, 2024 |
Exhibit 99.1 LETTER OF TRANSMITTAL AND CONSENT Offer to Exchange Warrants to Acquire Class A Ordinary Shares of Zura Bio Limited for Class A Ordinary Shares of Zura Bio Limited and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M., EASTERN TIME, ON AUGUST 8, 2024, OR SUCH LATER TIME AND DATE TO WHICH WE MAY EXTEND THE OFFER. |
|
| July 25, 2024 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporati |
|
| July 25, 2024 |
Exhibit 99.2 NOTICE OF GUARANTEED DELIVERY OF WARRANTS OF ZURA BIO LIMITED Pursuant to the Prospectus/Offer to Exchange, dated July 25, 2024, as amended Instructions for Use Unless defined herein, terms used in this notice of guaranteed delivery (this “Notice of Guaranteed Delivery”) shall have the definitions set forth in the prospectus/offer to exchange, dated July 25, 2024 (as amended or supple |
|
| July 25, 2024 |
Settlement Agreement by and between Zura Bio Limited and Someit Sidhu dated July 24, 2024 Exhibit 10.1 Dated July 24, 2024 ZURA BIO LIMITED and SOMEIT SIDHU SETTLEMENT AGREEMENT WITHOUT PREJUDICE AND SUBJECT TO CONTRACT THIS AGREEMENT is made on July 24, 2024 BETWEEN: (1) Zura Bio Limited a company incorporated and registered in England and Wales with company number 13856620 and whose registered office is at 3rd Floor 1 Ashley Road, Altrincham, Cheshire, United Kingdom, WA14 2DT (the " |
|
| July 25, 2024 |
Exhibit 99.3 LETTER TO BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES, AND OTHER NOMINEES Offer to Exchange Warrants to Acquire Class A Ordinary Shares of Zura Bio Limited for Class A Ordinary Shares of Zura Bio Limited and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (EACH AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M., EASTERN TIME, ON AUGUST 8, 2024, OR SUCH L |
|
| July 25, 2024 |
Giovanni Caruso Partner 345 Park Avenue New York, NY 10154 Direct 212.407.4866 Main 212.407.4000 Fax 212.937.3943 [email protected] Via EDGAR July 25, 2024 Brian Soares and Tina Chalk Division of Corporation Finance Office of Mergers & Acquisitions U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Zura Bio Ltd Schedule TO-I filed July |
|
| July 25, 2024 |
As filed with the U.S. Securities and Exchange Commission on July 25, 2024. TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on July 25, 2024. Registration No. 333-280763 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZURA BIO LIMITED (Exact name of registrant as specified in its charter) Cayman Islands 2834 98-172573 (State or other juri |
|
| July 25, 2024 |
Exhibit 99.4 LETTER TO CLIENTS OF BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES, AND OTHER NOMINEES Offer to Exchange Warrants to Acquire Class A Ordinary Shares of Zura Bio Limited for Class A Ordinary Shares of Zura Bio Limited and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (EACH AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M., EASTERN TIME, ON AUGUST 8, 2024 |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) ZURA BIO LIMITED (Name of Subject Company and Filing Person (Issuer)) Warrants to Acquire Class A Ordinary Shares G9TY5A119 (Title of Class of Securities) (CUSIP Number of Class of Securities) Robert L |
|
| July 25, 2024 |
Exhibit 10.1 Dated July 24, 2024 ZURA BIO LIMITED and SOMEIT SIDHU SETTLEMENT AGREEMENT WITHOUT PREJUDICE AND SUBJECT TO CONTRACT THIS AGREEMENT is made on July 24, 2024 BETWEEN: (1) Zura Bio Limited a company incorporated and registered in England and Wales with company number 13856620 and whose registered office is at 3rd Floor 1 Ashley Road, Altrincham, Cheshire, United Kingdom, WA14 2DT (the " |
|
| July 25, 2024 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporati |
|
| July 12, 2024 |
Exhibit 107 Calculation of Filing Fee Table SC TO-I (Form Type) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to Be Paid $ 6,086,000 (1) 0. |
|
| July 12, 2024 |
Form of Letter of Transmittal and Consent. Exhibit (a)(1)(B) LETTER OF TRANSMITTAL AND CONSENT Offer to Exchange Warrants to Acquire Class A Ordinary Shares of Zura Bio Limited for Class A Ordinary Shares of Zura Bio Limited and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P. |
|
| July 12, 2024 |
Form of Letter to Clients of Brokers, Dealers, Commercial Banks, Trust Companies, and Other Nominees Exhibit 99.4 LETTER TO CLIENTS OF BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES, AND OTHER NOMINEES Offer to Exchange Warrants to Acquire Class A Ordinary Shares of Zura Bio Limited for Class A Ordinary Shares of Zura Bio Limited and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (EACH AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M., EASTERN TIME, ON AUGUST 8, 2024 |
|
| July 12, 2024 |
Exhibit 10.49 DEALER MANAGER AGREEMENT July 11, 2024 Cantor Fitzgerald & Co. 110 East 59th Street New York, NY 10022 Ladies and Gentlemen: Zura Bio Limited, a Cayman Islands exempted company (the “Company” or “we”), plans to make an offer (such offer as described in the Prospectus (as defined below), together with the related Consent Solicitation (as defined below), the “Exchange Offer”), for any |
|
| July 12, 2024 |
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation Exhibit 99.1 Zura Bio Commences Warrant Exchange Offer and Consent Solicitation Henderson, NV, July 12, 2024 – Zura Bio Limited (NASDAQ: ZURA) (“Zura Bio” or the “Company”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consen |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ZURA BIO LIMITED (Name of Subject Company and Filing Person (Issuer)) Warrants to Acquire Class A Ordinary Shares G9TY5A119 (Title of Class of Securities) (CUSIP Number of Class of Securities) Robert Lisicki 1489 W. War |
|
| July 12, 2024 |
As filed with the U.S. Securities and Exchange Commission on July 11, 2024. TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on July 11, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZURA BIO LIMITED (Exact name of registrant as specified in its charter) Cayman Islands 2834 98-172573 (State or other jurisdiction of incorpor |
|
| July 12, 2024 |
Press Release, dated July 12, 2024. Exhibit (a)(5) Zura Bio Commences Warrant Exchange Offer and Consent Solicitation Henderson, NV, July 12, 2024 – Zura Bio Limited (NASDAQ: ZURA) (“Zura Bio” or the “Company”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its outstanding (i) public warrants that were issued in connection with its initial public offering to purchase Class A ordinary shares of the Company, par value $0. |
|
| July 12, 2024 |
Tax Opinion of Loeb & Loeb LLP. Exhibit (h) Loeb & Loeb LLP 10100 Santa Monica Blvd. Suite 2200 Los Angeles, CA 90067 Main 310.282.2000 Fax 310.282.2200 July 11, 2024 Zura Bio Limited 1489 W. Warm Springs Rd. #110 Henderson, NV 89014 Re: Registration Statement on Form S-4 Ladies and Gentlemen: We have acted as counsel to Zura Bio Limited (“Company”), a Cayman Islands exempted company, in connection with the Registration Statemen |
|
| July 12, 2024 |
Form of Notice of Guaranteed Delivery. Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY OF WARRANTS OF ZURA BIO LIMITED Pursuant to the Prospectus/Offer to Exchange, dated July 11, 2024 Instructions for Use Unless defined herein, terms used in this notice of guaranteed delivery (this “Notice of Guaranteed Delivery”) shall have the definitions set forth in the prospectus/offer to exchange, dated July 11, 2024 (as amended or supplemented from time to time, the “Prospectus/Offer to Exchange”). |
|
| July 12, 2024 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies, and Other Nominees Exhibit 99.3 LETTER TO BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES, AND OTHER NOMINEES Offer to Exchange Warrants to Acquire Class A Ordinary Shares of Zura Bio Limited for Class A Ordinary Shares of Zura Bio Limited and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (EACH AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M., EASTERN TIME, ON AUGUST 8, 2024, OR SUCH L |
|
| July 12, 2024 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies, and Other Nominees. Exhibit (a)(1)(D) LETTER TO BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES, AND OTHER NOMINEES Offer to Exchange Warrants to Acquire Class A Ordinary Shares of Zura Bio Limited for Class A Ordinary Shares of Zura Bio Limited and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (EACH AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P. |
|
| July 12, 2024 |
Exhibit (d)(xxxxxxii) DEALER MANAGER AGREEMENT July 11, 2024 Cantor Fitzgerald & Co. |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 ZURA BIO LIMITED (Exact name of Registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 12, 2024 |
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation Exhibit 99.1 Zura Bio Commences Warrant Exchange Offer and Consent Solicitation Henderson, NV, July 12, 2024 – Zura Bio Limited (NASDAQ: ZURA) (“Zura Bio” or the “Company”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consen |
|
| July 12, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-4 (Form Type) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Class A Ordinary Shares 457(f) (1) 3,842,999 (1)(2) $ 3,495 (3) $ 13,431,281. |
|
| July 12, 2024 |
Exhibit (d)(xxxxxxiii) TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of July 11, 2024, is entered into by and among Zura Bio Limited, a Cayman Islands exempted company (the “Company”), each of the persons listed on Schedule A hereto (each, a “Public Warrant Holder”) and each of the persons listed on Schedule B hereto (each, a “Private Warrant Holder” and, together with the Public Warrant Holders, the “IPO Warrant Holders,” and each, an “IPO Warrant Holder”). |
|
| July 12, 2024 |
Form of Letter of Transmittal and Consent. Exhibit 99.1 LETTER OF TRANSMITTAL AND CONSENT Offer to Exchange Warrants to Acquire Class A Ordinary Shares of Zura Bio Limited for Class A Ordinary Shares of Zura Bio Limited and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M., EASTERN TIME, ON AUGUST 8, 2024, OR SUCH LATER TIME AND DATE TO WHICH WE MAY EXTEND THE OFFER. |
|
| July 12, 2024 |
Form of Notice of Guaranteed Delivery Exhibit 99.2 NOTICE OF GUARANTEED DELIVERY OF WARRANTS OF ZURA BIO LIMITED Pursuant to the Prospectus/Offer to Exchange, dated July 11, 2024 Instructions for Use Unless defined herein, terms used in this notice of guaranteed delivery (this “Notice of Guaranteed Delivery”) shall have the definitions set forth in the prospectus/offer to exchange, dated July 11, 2024 (as amended or supplemented from |
|
| July 12, 2024 |
Exhibit 10.50 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of July 11, 2024, is entered into by and among Zura Bio Limited, a Cayman Islands exempted company (the “Company”), each of the persons listed on Schedule A hereto (each, a “Public Warrant Holder”) and each of the persons listed on Schedule B hereto (each, a “Private Warrant Holder” and, toget |
|
| July 12, 2024 |
Exhibit (a)(1)(E) LETTER TO CLIENTS OF BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES, AND OTHER NOMINEES Offer to Exchange Warrants to Acquire Class A Ordinary Shares of Zura Bio Limited for Class A Ordinary Shares of Zura Bio Limited and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (EACH AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P. |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 ZURA BIO LIMITED (Exact name of Registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 12, 2024 |
Prospectus/Offer to Exchange (incorporated by reference to Exhibit (a)(1)(A) herein). TABLE OF CONTENTS The information in this document may change. The registrant may not complete the offer and issue these securities until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This document is not an offer to sell these securities and it is not soliciting an offer to buy these securities, nor shall there be any sale of these securities, in |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 March 24, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission |
|
| June 18, 2024 |
As filed with the Securities and Exchange Commission on June 18, 2024. Table of Contents As filed with the Securities and Exchange Commission on June 18, 2024. |
|
| June 14, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 14, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporatio |
|
| June 14, 2024 |
Exhibit 99.1 Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024 Tibulizumab (ZB-106) was well tolerated and neutralized IL-17A and BAFF in a Phase 1 study in patients with Sjogren’s syndrome Preclinical data demonstrating the potential of dual inhibition of IL-17A and BAFF in a rheumatoid arthritis animal model support clinical development Henderson, Nev – June 14, 2024 - Zu |
|
| June 6, 2024 |
Exhibit 99.1 Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology Henderson, Nev – June 6, 2024 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the formation of a Scientific Advisory Board (SAB) with leadi |
|
| June 6, 2024 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 6, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation |
|
| June 4, 2024 |
ZURA BIO LIMITED Resale of Up To 41,596,750 Class A Ordinary Shares Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-279719 PROSPECTUS ZURA BIO LIMITED Resale of Up To 41,596,750 Class A Ordinary Shares This prospectus relates to the resale from time to time by the selling securityholders named in this prospectus or their permitted transferees (collectively, the “Selling Securityholders”) of up to an aggregate of 41,596,750 Class A ordinary |
|
| June 3, 2024 |
Exhibit 99.1 Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024 Novel, dual-pathway antibody targeting IL-17A and BAFF is expected to enter Phase 2 development in systemic sclerosis in Q4 2024 and hidradenitis suppurativa in Q2 2025 Henderson, Nev – June 3, 2024 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bi |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 3, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission File |
|
| May 31, 2024 |
Filed Pursuant to Rule 424(b)(7) Registration No. 333-272628 PROSPECTUS SUPPLEMENT NO. 2 (To prospectus dated September 14, 2023) Zura Bio Limited Resale of 30,251,124 Class A Ordinary Shares Resale of 3,782,000 Pre-Funded Warrants to Purchase Class A Ordinary Shares Resale of 5,910,000 private placement warrants to Purchase Class A Ordinary Shares Issuance and Resale of up to 3,782,000 Class A Or |
|
| May 30, 2024 |
Zura Bio Limited 1489 W. Warm Springs Rd. #110 Henderson, NV 89014 Zura Bio Limited 1489 W. Warm Springs Rd. #110 Henderson, NV 89014 May 30, 2024 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell RE: Zura Bio Limited Registration Statement on Form S-1 (File No. 333-279719) Acceleration Request Requested Date: June 3, 2024 Requested Time: 4:00 P.M. Eastern Time |
|
| May 29, 2024 |
Zura Bio Announces Participation in June Investor Conferences Exhibit 99.1 Zura Bio Announces Participation in June Investor Conferences Henderson, Nev – May 29, 2024 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor conferences in June. Conference Details: Even |
|
| May 29, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 29, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission File |
|
| May 24, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Class A ordinary shares, par value $0. |
|
| May 24, 2024 |
As filed with the Securities and Exchange Commission on May 24, 2024. Table of Contents As filed with the Securities and Exchange Commission on May 24, 2024. |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 9, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission File |
|
| May 9, 2024 |
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights Exhibit 99.1 Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights – Ended Q1 2024 with $89.8 million in cash and closed oversubscribed $112.5 million private placement in April 2024 from new and existing leading life sciences institutional investors – Appointed Robert Lisicki as CEO and Kiran Nistala, M.B.B.S., Ph.D. as CMO – On track to initiate Phase 2 studies eva |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 00 |
|
| May 2, 2024 |
ZURA / Zura Bio Limited / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment SC 13G 1 tm2413405d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Zura Bio Limited (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G9TY5A101 (CUSIP Number) April 22, 2024 (Date of Event Which Requires Filing of this Statement) Chec |
|
| May 2, 2024 |
ZURA / Zura Bio Limited / Venrock Healthcare Capital Partners III, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Zura Bio Limited (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G9TY5A101 (CUSIP Number) April 22, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| April 23, 2024 |
Exhibit 4.1 THE OFFER AND SALE OF THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATIO |
|
| April 23, 2024 |
Zura Bio Announces Oversubscribed $112.5 Million Private Placement Exhibit 99.2 Zura Bio Announces Oversubscribed $112.5 Million Private Placement - Financing includes new and existing leading life sciences institutional investors - Strengthened balance sheet expected to fund operations through 2027 Henderson, Nev – April 18, 2024 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibod |
|
| April 23, 2024 |
Exhibit 10.1 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this “Subscription Agreement” or “Agreement”) is entered into on April 18, 2024, by and between Zura Bio Limited, a Cayman Islands exempted company (the “Company”), and the subscriber named on the signature page hereto (“Subscriber”). WHEREAS, Subscriber desires to subscribe for and purchase from the Company, (i) that number of Class |
|
| April 23, 2024 |
Exhibit 99.1 ©2024 Zura Bio Ltd. Nasdaq Ticker: ZURA Advancing clinical outcomes through pioneering dual-pathway biology April 2024 ©2024 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “projec |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission F |
|
| April 22, 2024 |
ZURA / Zura Bio Limited / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 8, 2024 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 8, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporatio |
|
| April 8, 2024 |
Zura Bio Announces Robert Lisicki as CEO and Director Exhibit 99.1 Zura Bio Announces Robert Lisicki as CEO and Director - Succeeds Founding CEO, Dr. Someit Sidhu, who will continue as a Board Director - Recognized as inspirational industry leader with exceptional R&D, commercial and global executive experience - Outstanding product development and commercialization track record across a number of leading I&I therapies spanning nearly 30 years Hender |
|
| March 28, 2024 |
Exhibit 97 ZURA BIO LIMITED INCENTIVE COMPENSATION RECOUPMENT POLICY Effective: November 29, 2023 1. |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-405 |
|
| March 28, 2024 |
Exhibit 99.1 Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer - Significant 2023 milestones highlighted by successful Nasdaq listing, leadership team buildout, formation of strategic development and scientific plan - On track to initiate Phase 2 study evaluating tibulizumab (ZB-106) for the treatment of systemic sclerosi |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 24, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 28, 2024 |
Exhibit 4.2 DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED General We are a company incorporated in the Cayman Islands as an exempted company and our affairs are governed by the MAA, the Cayman Islands Companies Act and the common law of the Cayman Islands. Pursuant to the MAA, our authorized share capital consists of 30 |
|
| March 11, 2024 |
Exhibit 99.1 ©2024 Zura Bio Ltd. Nasdaq Ticker: ZURA Building the Next Immunology Leader March 2024 ©2024 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “antic |
|
| March 11, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 11, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 4, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 4, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporatio |
|
| March 4, 2024 |
Zura Bio Announces Participation at March Conferences Exhibit 99.1 Zura Bio Announces Participation at March Conferences Henderson, Nev – March 4, 2024 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will participate in three conferences in March. Conference Details: |
|
| February 23, 2024 |
Exhibit 16.1 February 23, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Zura Bio Limited (formerly JATT Acquisition Corp.) under Item 4.01 of its Form 8-K dated February 23, 2024. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements |
|
| February 23, 2024 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission F |
|
| February 14, 2024 |
ZURA / Zura Bio Limited / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-zura123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ZURA BIO LIMITED (Name of Issuer) Class A Ordinary Shares, $0.0001 par value (Title of Class of Securities) G9TY5A101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 14, 2024 |
ZURA / Zura Bio Limited / GREAT POINT PARTNERS LLC Passive Investment SC 13G/A 1 greatpoint-zura123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ZURA BIO LIMITED (Name of Issuer) Class A Ordinary Shares, $0.0001 par value (Title of Class of Securities) G9TY5A101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check th |
|
| February 14, 2024 |
ZURA / Zura Bio Limited / ACCESS INDUSTRIES MANAGEMENT, LLC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Zura Bio Limited (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G9TY5A101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2024 |
EX-99.1 2 d786149dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree that the Statement on Schedule 13G to which this Exhibit is attached is filed on behalf of each of them. Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached. Each of |
|
| February 13, 2024 |
JATT / JATT Acquisition Corp - Class A / GLAZER CAPITAL, LLC Passive Investment SC 13G/A 1 jatt20231231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Zura Bio Limited (formerly known as JATT Acquisition Corp) (Name of Issuer) Class A Ordinary Shares (Title of Class of Securities) G50752107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| February 12, 2024 |
ZURA / Zura Bio Limited / Alberta Investment Management Corp - SC 13G/A Passive Investment SC 13G/A 1 d776631dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) ZURA BIO LIMITED (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G9TY5A101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| February 6, 2024 |
ZURA / Zura Bio Limited / Hudson Bay Capital Management LP - ZURA 13G/A Passive Investment SC 13G/A 1 zura13ga.htm ZURA 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Zura Bio Limited (formerly known as JATT Acquisition Corp) (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G9TY5A101 (CUSIP Number) December 31, 2023 (Date of Event Which Require |
|
| February 2, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 2, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission |
|
| February 2, 2024 |
Zura Bio Announces Participation at February Investor Conferences Exhibit 99.1 Zura Bio Announces Participation at February Investor Conferences Henderson, Nev – February 2, 2024 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will participate at several upcoming conferences in |
|
| January 25, 2024 |
JATT / JATT Acquisition Corp - Class A / Magnetar Financial LLC - SC 13G/A Passive Investment SC 13G/A 1 tm243910d20sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 – Exit Filing)* ZURA BIO LIMITED (Name of Issuer) Common Stock – Class A (Title of Class of Securities) G50752107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| January 25, 2024 |
Joint Filing Agreement, dated as of January 25, 2024, among the Reporting Persons. EX-99.1 2 tm243910d20ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Shares of ZURA BIO LIMITED dated as of December 31, 2023 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with |
|
| January 25, 2024 |
Power of Attorney, dated as of December 22, 2022 filed by the Reporting Persons on January 25, 2024. EX-99.2 3 tm243910d20ex99-2.htm EXHIBIT 99.2 EXHIBIT 99.2 LIMITED POWER OF ATTORNEY Know all by these present, that I, David J. Snyderman, hereby make, constitute and appoint each of Michael Turro, Karl Wachter and Hayley Stein, or any of them acting individually, and with full power of substitution, as my true and lawful attorney-in-fact for the purpose of executing in my name, (a) in my personal |
|
| January 11, 2024 |
Exhibit 99.1 ©2024 Zura Bio Ltd. Nasdaq Ticker: ZURA Building the Next Immunology Leader 42nd Annual J.P. Morgan Healthcare Conference January 11, 2024 San Francisco, California ©2024 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 199 |
|
| January 11, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 11, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission |
|
| January 8, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) dated as of January 3, 2024 is by and between Zura Bio Inc. (a subsidiary of Zura Bio Limited) (the “Company”), and Rob Lisicki (“Executive”). WHEREAS, the Company desires to enter into this Agreement with Executive pursuant to which Executive will serve as the President and Chief Operating Officer of the Company effecti |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 3, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission F |
|
| January 8, 2024 |
Exhibit 99.1 Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO • Accomplished biopharmaceutical executives bring invaluable expertise and experience to Zura Bio’s Clinical Development programs • Executive Leadership hires position Zura Bio for Phase 2 clinical trial readiness across multiple indications in 2024 Henderson, Nev – Jan |
|
| January 3, 2024 |
Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit Exhibit 99.1 Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit Henderson, Nev – January 3, 2024 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will present at two upc |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 3, 2024 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission F |
|
| December 14, 2023 |
ZURA / Zura Bio Ltd - Class A / Athanor Capital, Lp Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No.) * ZURA BIO LIMITED (Name of Issuer) COMMON STOCK (Title of Class of Securities) G9TY5A101 (CUSIP Number) December 12, 2023 (Date of Event Which Requires Filing |
|
| December 6, 2023 |
Exhibit 10.1 Dated 30 November 2023 ZURA BIO LIMITED and KIRAN NISTALA SERVICE AGREEMENT THIS AGREEMENT is entered into between the parties on November 30, 2023 PARTIES (1) Zura Bio Limited a company incorporated and registered in England and Wales with company number 13856620 and whose registered office is at 3rd Floor 1 Ashley Road, Altrincham, Cheshire, United Kingdom, WA14 2DT (the "Company"); |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 30, 2023 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission |
|
| December 4, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 4, 2023 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission |
|
| December 4, 2023 |
Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok Exhibit 99.1 Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok Henderson, Nev – December 4, 2023 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced two abstracts were accepted and presented at World Allergy Congres |
|
| November 14, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 14, 2023 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission |
|
| November 14, 2023 |
Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors Exhibit 99.1 Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors Henderson, Nev – November 14, 2023 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the Board of Directors appointed Arnout Ploos van Amstel as Non-Executive Independent Director by |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Numbe |
|
| October 25, 2023 |
Exhibit 99.1 ©2023 Zura Bio Ltd. Corporate Overview Last Updated: October 2023 Building the Next Immunology Leader ©2023 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “ |
|
| October 25, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 24, 2023 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission |
|
| October 16, 2023 |
Filed Pursuant to Rule 424(b)(7) Registration No. 333-272628 PROSPECTUS SUPPLEMENT NO. 1 (To prospectus dated September 14, 2023) Zura Bio Limited Resale of 30,251,124 Class A Ordinary Shares Resale of 3,782,000 Pre-Funded Warrants to Purchase Class A Ordinary Shares Resale of 5,910,000 Private Placement Warrants to Purchase Class A Ordinary Shares Issuance and Resale of up to 3,782,000 Class A Or |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 22, 2023 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 14, 2023 |
Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute Exhibit 99.1 Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute · Benaroya Research Institute to further characterize role of IL-7Rα in TSLP and IL-7 signaling pathways · Agreement underscores Zura Bio’s commitment to advancing science in immune-mediated disorders September 12, 2023 05:00 AM Eastern Daylight Time HENDERSON, Nev.-(BUSINESS WIRE)-Zura Bio Limited (Nas |
|
| September 14, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 12, 2023 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commissio |
|
| September 14, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-272628 PROSPECTUS ZURA BIO LIMITED Resale of 30,251,124 Class A Ordinary Shares Resale of 3,782,000 Pre-Funded Warrants to Purchase Class A Ordinary Shares Resale of 5,910,000 Private Placement Warrants to Purchase Class A Ordinary Shares Issuance and Resale of up to 3,782,000 Class A Ordinary Shares issuable upon the exerci |
|
| September 12, 2023 |
Zura Bio Limited 1489 W. Warm Springs Rd. #110 Henderson, NV 89014 Zura Bio Limited 1489 W. Warm Springs Rd. #110 Henderson, NV 89014 September 12, 2023 VIA EDGAR U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 RE: Zura Bio Limited (the “Company”) Registration Statement on Form S-1 (File No. 333-272628) (the “Registration Statement”) Ladies and Gentlemen: The Company hereby requests, pursuant to Rule 461 promulgated under the Securit |
|
| September 11, 2023 |
As filed with the Securities and Exchange Commission on September 8, 2023. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 8, 2023. |
|
| September 8, 2023 |
Giovanni Caruso Partner 345 Park Avenue New York, NY 10154 Direct 212.407.4866 Main 212.407.4000 Fax 212.937.3943 [email protected] Via Edgar September 8, 2023 Dillon Hagius Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Zura Bio Limited Amendment No. 3 to Registration Statement on Form S-1 Filed August 2 |
|
| August 25, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-1 (Form Type) ZURA BIO LIMITED (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A ordinary shares, par value $0. |
|
| August 25, 2023 |
As filed with the Securities and Exchange Commission on August 24, 2023. Table of Contents As filed with the Securities and Exchange Commission on August 24, 2023. |
|
| August 24, 2023 |
Giovanni Caruso Partner 345 Park Avenue New York, NY 10154 Direct 212.407.4866 Main 212.407.4000 Fax 212.407.4990 [email protected] Via Edgar August 24, 2023 Dillon Hagius Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Zura Bio Limited Amendment No. 2 to Registration Statement on Form S-1 Filed August 11, |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2023 Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporation) (Commission |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001 |
|
| August 14, 2023 |
Zura Bio Limited Condensed Consolidated Balance Sheets (In thousands, except share data) Exhibit 99.1 Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights • Focused on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist for systemic sclerosis and hidradenitis suppurativa • Experienced team building the next immunology leader • Cash and cash equivalents of $113 million support development and operations through 2026 Hen |
|
| August 11, 2023 |
Exhibit 10.38 EXECUTION VERSION CONFIDENTIAL CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT NORMALLY TREATS AS PRIVATE AND CONFIDENTIAL. LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT DATED AS OF APRIL 26, 2023 BY AND BETWEEN ELI LILLY AND COMPANY AND ZB17 LLC TABLE OF CONTENTS Page ARTICLE 1 DEFINI |
|
| August 11, 2023 |
Giovanni Caruso Partner 345 Park Avenue New York, NY 10154 Direct 212.407.4866 Main 212.407.4000 Fax 212.407.4990 [email protected] Via Edgar August 11, 2023 Dillon Hagius Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Zura Bio Limited Registration Statement on Form S-1 Filed July 21, 2023 File No. 333-27 |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 11, 2023. |
|
| August 11, 2023 |
Exhibit 10.39 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT NORMALLY TREATS AS PRIVATE AND CONFIDENTIAL. November 22, 2022 Kimberly Davis Dear Kim, I am delighted to make you an offer for the position of Executive Vice President, Chief Legal Officer & General Counsel for the Zura Bio Group (including Zur |
|
| July 27, 2023 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2023 Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporati |
|
| July 27, 2023 |
Building the Next Immunology Leader Corporate Presentation – July 2023 Exhibit 99.1 Building the Next Immunology Leader Corporate Presentation – July 2023 ©2023 Zura Bio Ltd. This communication includes “ forward - looking statements ” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 . Words such as “ expect ,” “ estimate ,” “ project ,” “ budget ,” “forecast,” “ anticipate,” “ intend,” “ plan,” “ may,” “ will |
|
| July 21, 2023 |
Giovanni Caruso Partner 345 Park Avenue New York, NY 10154 Direct 212.407.4866 Main 212.407.4000 Fax 212.937.3943 [email protected] Via Edgar July 21, 2023 Dillon Hagius Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Zura Bio Limited Registration Statement on Form S-1 Filed June 14, 2023 File No. 333-2726 |
|
| July 21, 2023 |
As filed with the Securities and Exchange Commission on July 21, 2023. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 21, 2023. |
|
| June 23, 2023 |
Zura Bio to Join the Russell 2000® and Russell 3000® Indexes Exhibit 99.1 Zura Bio to Join the Russell 2000® and Russell 3000® Indexes SAN DIEGO, California - June 23, 2023 - Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio” or the “Company”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced it will be added to the Russell 2000® and Russell 3000® Indexes at the conclu |
|
| June 23, 2023 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 23, 2023 Date of Report (Date of earliest event reported) Zura Bio Limited (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporatio |
|
| June 22, 2023 |
As filed with the Securities and Exchange Commission on June 22, 2023 As filed with the Securities and Exchange Commission on June 22, 2023 Registration No. |
|
| June 22, 2023 |
Calculation of Filing Fees Table Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) ZURA BIO LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A ordinary shares, par value $0. |
|
| June 22, 2023 |
ZURA / Zura Bio Ltd - Class A / Athanor Capital, Lp - SCHEDULE 13D/A Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Zura Bio Limited (Name of Issuer) Class A Ordinary Shares, $0.0001 par value per share (Title of Class of Securities) G011FJXV49 (CUSIP Number) Athanor Capital, L.P. 142 W57th Street Suite 09-126, 11th Floor for Mail New York, NY 10019 Attn: |
|
| June 16, 2023 |
ZURA / Zura Bio Ltd - Class A / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 15, 2023 |
Building the Next Immunology Leader Last Updated: June 2023 zurabio Corporate Overview Exhibit 99.1 Building the Next Immunology Leader Last Updated: June 2023 zurabio Corporate Overview Disclaimer Forward Looking Statements Disclaimer This communication includes “ forward - looking statements ” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 . Words such as “ expect ,” “ estimate ,” “ project ,” “ budget ,” “forecast,” “ an |
|
| June 15, 2023 |
EX-99.2 3 d517042dex992.htm EX-99.2 Exhibit 99.2 LIMITED POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lincoln Benet and Alejandro Moreno, and each of them individually, the undersigned’s true and lawful attorney-in-fact to: • execute for and on behalf of the undersigned, in the undersigned’s capacity as a beneficial owner of Zura Bio Limited (t |
|
| June 15, 2023 |
ZURA / Zura Bio Ltd - Class A / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 15, 2023 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree that the Statement on Schedule 13G to which this Exhibit is attached is filed on behalf of each of them. Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached. Each of them is responsible for the |
|
| June 15, 2023 |
ZURA / Zura Bio Ltd - Class A / ACCESS INDUSTRIES MANAGEMENT, LLC - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Zura Bio Limited (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G9TY5A101 (CUSIP Number) June 5, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| June 15, 2023 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2023 Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporati |
|
| June 15, 2023 |
ZURA / Zura Bio Ltd - Class A / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 14, 2023 |
As filed with the Securities and Exchange Commission on June 13, 2023. Table of Contents As filed with the Securities and Exchange Commission on June 13, 2023. |
|
| June 14, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-1 (Form Type) ZURA BIO LIMITED (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A ordinary shares, par value $0. |
|
| June 6, 2023 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2023 (June 5, 2023) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction |
|
| June 6, 2023 |
Exhibit 99.1 Zura Bio completes approximately $80 Million financing with the focus on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist § Tibulizumab (ZB-106) was licensed from Eli Lilly and Company on April 26, 2023 § Total cash and cash equivalents of approximately $120 million is expected to fund planned clinical and operating activities through 2026 SAN DIEG |
|
| June 2, 2023 |
Zura Bio Limited 2023 Equity Incentive Plan Exhibit 10.1 ZURA BIO LIMITED 2023 EQUITY INCENTIVE PLAN (As Amended June 1, 2023) 1. Purpose The purpose of this Zura Bio Limited 2023 Equity Incentive Plan (the “Plan”) is to promote and closely align the interests of employees, officers, non- employee directors and other service providers of Zura Bio Limited, a Cayman Islands exempted company formerly known as JATT Acquisition Corp (the “Compan |
|
| June 2, 2023 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2023 Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporatio |
|
| May 19, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 00 |
|
| May 12, 2023 |
Exhibit 10.28 Zura Bio Inc. Electronically Delivered Personal and Confidential March 2, 2023 Amit Munshi +1 805 490 1389 | [email protected] Dear Amit, Position: Chairman of the Board of Directors We are pleased to offer you the position Chairman of Zura Bio Inc. (the “Private Company”) subject to the terms and conditions set forth below. Additionally, following the closing (“Closing”) of the Priva |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| May 3, 2023 |
Exhibit 4.1 PURSUANT TO THE TERMS OF SECTION 1 OF THIS WARRANT, ALL OR A PORTION OF THIS WARRANT MAY HAVE BEEN EXERCISED OR CANCELED, AND THEREFORE THE ACTUAL NUMBER OF WARRANT SHARES REPRESENTED BY THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF. ANY TRANSFEREE OF THIS WARRANT SHOULD CONTACT ZURA BIO LIMITED IN ADVANCE OF ACQUIRING THIS WARRANT TO BE APPRISED OF THE ACTUAL |
|
| May 3, 2023 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2023 (April 26, 2023) Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction |
|
| May 3, 2023 |
Exhibit 10.1 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this “Subscription Agreement” or “Agreement”) is entered into on April 26, 2023, by and between Zura Bio Limited, a Cayman Islands exempted company (the “Company”), and the subscriber named on the signature page hereto (“Subscriber”). WHEREAS, Subscriber desires to subscribe for and purchase from the Company, that number of Class A o |
|
| April 27, 2023 |
Warrants [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 27, 2023 Zura Bio Limited (Exact name of registrant as specified in its charter) Cayman Islands 001-40598 98-1725736 (State or other jurisdiction of incorporat |
|
| April 27, 2023 |
Building the Next Immunology Leader April 2023 zurabio Corporate Overview with ZB - 106 Deep - Dive Exhibit 99.2 Building the Next Immunology Leader April 2023 zurabio Corporate Overview with ZB - 106 Deep - Dive Disclaimer This presentation (this “ Presentation ”) has been prepared by Zura Bio Limited, together with its affiliates (the “ Company ” ) and is being furnished to certain potential investors in the Company . Guggenheim Securities, LLC and Raymond James (together, the " Placement Agen |
|
| April 27, 2023 |
Exhibit 99.1 Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases § Licensing a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist § In connection with the transaction, Zura Bio announces pricing of $80 million private placement financing SAN DIEGO, California |
